|
Prior to cofounding Immunotope, Dr. Philip was the Senior Vice President of Protein Discovery at RHeoGene LLC, and before that was head of Research, Product and Business Development at Argonex Pharmaceuticals, (a fully owned subsidiary of Upstate Group Inc.) and Vice President of Product Development and Scientific Affairs at Upstate Inc. At Argonex and Upstate, Dr. Philip developed proteomics platform technologies and immunotherapy target discovery strategies. Her work included antigen discovery for melanoma, prostate and ovarian cancer and tuberculosis. Dr. Philip established several collaborative protein discovery agreements while at Upstate, including EuroProteome SA, Incyte, and Anosys. During her tenure at Upstate, her group obtained FDA approval of an orphan drug application for melanoma immunotherapy. Prior to Upstate, Dr. Philip was the Senior Director of Oncology and Gene Therapy at Rhone Poulenc Rorer Gencell. Dr. Philip developed several immunotherapy and gene therapy products from research to early phase clinical testing at RPR Gencell, including Phases I-III for a renal cancer cell therapy product with Dr. Kim Lyerly, a Phase I gene therapy vaccine for breast cancer with Dr. Johannes Vieweg (Duke University) and a Phase I melanoma vaccine with Dr. Jeff Weber (USC). Prior to joining RPR Gencell, Dr. Philip was an Assistant Research Immunologist at UCSF and worked at the cancer research institute for 6 years. Dr. Philip earned her Ph.D. in Immunology in India and did her postdoctoral training at the Institute of Immunology, Basel, Switzerland. Dr. Philip has over 15 years of experience in biotech industry and has developed several biotherapeutic products. She has over 50 publications in major scientific journals. | 